Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

NEW HAVEN, Conn., Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 5,263,158 of its common shares at a price to the public of $47.50 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 789,47 ...